Free radical scavengers: Chemical concepts and clinical relevance

Journal of Neural Transmission, Supplement

Volumn , Issue 56, 1999, Pages 193-210

  Gassen, Michael ^a   Youdim, M B H ^b  

^a MERCK KGAA   (Germany)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; DOPAMINE; FREE RADICAL; REACTIVE OXYGEN METABOLITE; SCAVENGER; ANTIOXIDANT;

ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; CONFERENCE PAPER; HUMAN; LIPID PEROXIDATION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; ANIMAL; CHEMISTRY; REVIEW;

ANIMALS; ANTIOXIDANTS; FREE RADICAL SCAVENGERS; FREE RADICALS; HUMANS; PARKINSON DISEASE;

EID: 0032588333     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-6360-3_13     Document Type: Conference Paper

References (83)

1. Anghileri LJ, Maincent P, Cordova MA, Thouvenot P (1994) The role of ATP as a mediator in the action of iron complexes on cellular calcium homeostasis. Biol Trace Elem Res 46: 103-111
2. Ben-Shachar D, Riederer P, Youdim MBH (1991) Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease. J Neurochem 57: 1609-1614
3. Ben-Shachar D, Livne E, Spanier I, Zuk R, Youdim MBH (1993) Iron modulates neuroleptic-induced effects related to the dopaminergic system. Isr J Med Sci 29: 587-592
4. 3 uptake. J Neurochem 62: 1112-1118
5. Benov LC, Benchev IC, Monovich OH (1990) Thiol antidotes effect on lipid peroxidation in mercury-poisoned rats. Chem Biol Interact 76: 321-332
6. Cadet JL, Ali S, Epstein C (1994) Involvement of oxygen-based radicals in methamphetamine-induced neurotoxicity: evidence from the use of CuZnSOD transgenic mice. Ann N Y Acad Sci 738: 388-391
7. Cao X, Phillis JW (1995) The free radical scavenger, α-lipoic acid, protects against cerebral ischemia-reperfusion injury in gerbils. Free Radic Res 23: 365-370
8. Carney JM, Kindy MS, Smith CD, Wood K, Tatsuno T, Wu JF, Landrum WR, Floyd RA (1994) Gene expression and functional changes after acute ischemia: age-related differences in outcome and mechanisms. In: Hartmann A, Yatsu F, Kuschinsky W (eds) Cerebral ischemia and basic mechanisms. Springer, Berlin Heidelberg New York Tokyo, pp 301-311
9. Cerruti C, Sheng P, Ladenheim B, Epstein CJ, Cadet JL (1995) Involvement of oxidative and L-arginine-NO pathways in the neurotoxicity of drugs of abuse in vitro. Clin Exp Pharmacol Physiol 22: 381-382
10. Cheng HY, Liu T, Feuerstein G, Barone FC (1993) Distribution of spin-trapping compounds in rat blood and brain: in vivo microdialysis determination. Free Radic Biol Med 14: 243-250
11. +. Free Radic Biol Med 13: 581-583
12. Ciuffi M, Gentilini G, Franchi Micheli S, Zilletti L (1992) D-penicillamine affects lipid peroxidation and iron content in the rat brain cortex. Neurochem Res 17: 1241-1246
13. Colton CA, Pagan F, Snell J, Colton JS, Cummins A, Gilbert DL (1995) Protection from oxidation enhances the survival of cultured mesencephalic neurons. Exp Neurol 132: 54-61
14. Ercal N, Treeratphan P, Hammond TC, Matthews RH, Grannemann NH, Spitz DR (1996) In vivo indices of oxidative stress in lead-exposed C57BL/6 mice are reduced by treatment with meso-2,3-dimercaptosuccinic acid or N-acetylcysteine. Free Radic Biol Med 21: 157-161
15. Esterbauer H (1980) Aldehydes of lipid peroxidation. In: McBrien DCH, Slater TF (eds) Free radicals, peroxidation, and cancer. Academic Press, London, pp 101-122
16. Fahn S, Cohen G (1992) The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 32: 804-812
17. Ferrari G, Yan CY, Greene LA (1995) N-acetylcysteine (D-and L-stercoisomers) prevents apoptotic death of neuronal cells. J Neurosci 15: 2857-2866
18. Folbergrova J, Zhao Q, Katsura K, Siesjö BK (1995) N-tert-butyl-α-phenylnitrone improves recovery of brain energy state in rats following transient focal ischemia. Proc Natl Acad Sci USA 92: 5057-5061
19. Froissard P, Monrocq H, Duval D (1997) Role of glutathione metabolism in the glutamate-induced programmed cell death of neuronal-like PC12 cells. Eur J Pharmacol 326: 93-99
20. Galey JB, Dumats J, Beck I, Fernandez B, Hocquaux M (1995) N,N′-bis-dibenzyl ethylenediamincdiacetic acid (DBED): a site-specific hydroxyl radical scavenger acting as an "oxidative stress activatable" iron chelator in vitro. Free Radic Res 22: 67-86
21. Gancher ST, Nutt JG, Woodward WR (1995) Apomorphine infusional therapy in Parkinson's disease: clinical utility and lack of tolerance. Mov Disord 10: 37-43
22. Gassen M, Glinka Y, Pinchasi B, Youdim MBH (1996) Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. Eur J Pharmacol 308: 219-225
23. 2 and 6-hydroxydopamine. Mov Disord in press:
24. Gerlacli M, Riederer P, Przuntek H, Youdim MBH (1991) MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur J Pharmacol 208: 273-286
25. Gerlach M, Ben-Shachar D, Riederer P, Youdim MBH (1994) Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem 63: 793-807
26. Gerlach M, Riederer P, Youdim MBH (1996) Molecular mechanisms for neurodegeneration, Synergism between reactive oxygen species, calcium, and excitotoxic amino acids. Adv Neurol 69: 177-194
27. Giovanni A, Liang LP, Hastings TG, Zigmond MJ (1995) Estimating hydroxyl radical content in rat brain using systematic and intraventricular salicylate: impact of methamphetamine. J Neurochem 64: 1819-1825
28. Götz ME, Kunig G, Riederer P, Youdim MBH (1994) Oxidative stress: free radical production in neural degeneration. Pharmacol Ther 63: 37-122
29. Greene LA, Aletta JM, Rukenstein A, Green SH (1987) PC12 pheochromocytoma cells: culture, nerve growth factor treatment, and experimental exploitation. Methods Enzymol 147: 207-216
30. Haenen GR, Paquay JB, Korthouwer RE, Bast A (1997) Peroxynitrite scavenging by flavonoids. Biochem Biophys Res Commun 236: 591-593
31. Hall ED (1997) Antioxidant Therapeutic Strategies in CNS Disorders. In: Connor JR (ed) Metals and oxidative damage in neurological disorders. Plenum Press, New York, pp 325-339
32. Hall ED, McCall JM (1993) Lazaroids: potent inhibitors of iron-dependent lipid pcroxidation for neurodegenerative disorders. In: Riederer P, Youdim MBH (eds) Iron in central nervous system disorders. Springer, Wien New York, pp 173-188
33. Hall ED, Andrus PK, Yonkers PA (1993) Brain hydroxyl radical generation in acute experimental head injury. J Neurochem 60: 588-594
34. Hallenbeck JM (1996) Significance of the inflammatory response in brain ischemia. Acta Neurochir [Suppl] Wien 66: 27-31
35. Halliwell B, Gutteridge JMC (1985) Oxygen radicals and the nervous system. Trends Neurosci 8: 22-29
36. Haramaki N, Stewart DB, Aggarwal S, Kawabata T, Packer L (1995) Role of ascorbate in protection by nitecapone against cardiac ischemia-reperfusion injury. Biochem Pharmacol 50: 839-843
37. Harley A, Cooper JM, Schapira AH (1993) Iron induced oxidative stress and mitochondrial dysfunction: relevance to Parkinson's disease. Brain Res 627: 349-353
38. Hasinoff BB, Venkataram S, Singh M, Kuschak TI (1994) Metabolism of the cardioprotective agents dexrazoxane (ICRF-187) and levrazoxane (ICRF-186) by the isolated hepatocyte. Xenobiotica 24: 977-987
39. Hastings TG, Lewis DA, Zigmond MJ (1996) Reactive dopamine metabolites and neurotoxicity: implications for Parkinson's disease. Adv Exp Med Biol 387: 97-106
40. Hensley K, Carney JM, Steward CA, Tabatabaie T, Pye Q, Floyd RA (1997) Nitron-based free radical traps as neuroprotective agents in cerebral ischemia and other pathologies. In: Green AR, Cross AJ (eds) Neuroprotective agents in cerebral ischemia. Academic Press, San Diego, pp 299-317
41. Hershko C (1994) Control of disease by selective iron depletion: a novel therapeutic strategy utilizing iron chelators. Baillieres Clin Haematol 7: 965-1000
42. Hershko C, Link G, Tzahor M, Pinson A (1993) The role of iron and iron chelators in anthracycline cardiotoxicity. Leuk Lymphoma 11: 207-214
43. Hess DC, Thompson Y, Sprinkle A, Carroll J, Smith J (1996) E-selectin expression on human brain microvascular endothelial cells. Neurosci Lett 213: 37-40
44. Hider RC, Choudhury R, Rai BL, Dehkordi LS, Singh S (1996) Design of orally active iron chelators. Acta Haematol 95: 6-12
45. Hoyt KR, Reynolds IJ, Hastings TG (1997) Mechanisms of dopamine-induced cell death in cultured rat forebrain neurons: interactions with and differences from glutamate-induced cell death. Exp Neurol 143: 269-281
46. Hunter MIS, Nlemadim BC, Davidson DLW (1985) Lipid peroxidation production and antioxidant properties in plasma and cerebrospinal fluid of multiple sclerosis patients. Neurochem Res 10: 1645-1652
47. Janzen EG, Blackburn BJ (1968) Detection and identification of short-lived free radicals by an electron spin resonance trappind technique. J Am Chem Soc 90: 5909-5915
48. Janzen EG, Kotake Y, Hinton RD (1992) Stabilities of hydroxyl radical spin adducts of PBN-type spin traps. Free Radic Biol Med 12: 169-173
49. Jellinger K, Linert L, Kienzl E, Herlinger E, Youdim MBH, Ben-Shachar D, Riederer P (1996) Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease. J Neural Transm [Suppl] 57: 1609-1614
50. Kawabata T, Schepkin V, Haramaki N, Phadke RS, Packer L (1996) Iron coordination by catechol derivative antioxidants. Biochem Pharmacol 51: 1569-1577
51. Knuckey NW, Palm D, Primiano M, Epstein MH, Johanson CE (1995) N-acetylcysteine enhances hippocampal neuronal survival after transient forebrain ischemia in rats. Stroke 26: 305-310
52. Leenders KL, Antonini A, Schwarzbach R, Smith-Jones P, Reist H, Ben-Shachar D, Youdim MBH, Henn V (1994) Blood to brain iron uptake in one rhesus monkey using [Fe-52]-citrate and positron emission tomography (PET): influence of haloperidol. J Neural Transm [Suppl] 43: 123-132
53. Lees AJ (1993) Dopamine agonists in Parkinson's disease: a look at apomorphine. Fundam Clin Pharmacol 7: 121-128
54. Liehr JG (1997a) Dual role of oestrogens as hormones and pro-carcinogens: tumour initiation by metabolic activation of oestrogens. Eur J Cancer Prev 6: 3-10
55. Liehr JG (1997b) Hormone-associated cancer: mechanistic similarities between human breast cancer and estrogen-induced kidney carcinogenesis in hamsters. Environ Health Perspect 105 [Suppl] 3: 565-569
56. Liu J, Mori A (1993) Monoamine metabolism provides an antioxidant defense in the brain against oxidant-and free radical-induced damage. Arch Biochem Biophys 302: 118-127
57. Marx JJ, van Asbeck BS (1996) Use of iron chelators in preventing hydroxyl radical damage: adult respiratory distress syndrome as an experimental model for the pathophysiology and treatment of oxygen-radical-mediated tissue damage. Acta Haematol 95: 49-62
58. McCay PB (1985) Vitamin E: Interactions with free radicals and ascorbate. Ann Rev Nutr 5: 323-340
59. Miller JW, Selhub J, Joseph JA (1996) Oxidative damage caused by free radicals produced during catecholamine autoxidation: protective effects of O-methylation and melatonin. Free Radic Biol Med 21: 241-249
60. Minotti G, Aust SD (1992) Redox cycling of iron and lipid peroxidation. Lipids 27: 219-226
61. Morel I, Cillard J, Lescoat G, Sergent O, Pasdeloup N, Ocaktan AZ, Abdallah MA, Brissot P, Cillard P (1992) Antioxidant and free radical scavenging activities of the iron chelators pyoverdin and hydroxypyrid-4-ones in iron-loaded hepatocyte cultures: comparison of their mechanism of protection with that of desferrioxamine. Free Radic Biol Med 13: 499-508
62. Morel I, Lescoat G, Cogrel P, Sergent O, Pasdeloup N, Brissot P, Cillard P, Cillard J (1993) Antioxidant and iron-chelating activities of the flavonoids catechin, quercetin and diosmetin on iron-loaded rat hepatocyte cultures. Biochem Pharmacol 45: 13-19
63. Oliver CN, Starke-Reed FE, Stadtman ER, Liu GJ, Carney JM, Floyd RA (1990) Oxidative damage to brain proteins, loss of glutamine synthetase activity, and production of free radicals during ischemia/reperfusion-induced injury to gerbil brain. Proc Natl Acad Sci U S A 87: 5144-5147
64. Olivieri NF (1996) Long-term therapy with deferiprone. Acta Haematol 95: 37-48
65. Packer L, Tritschler HJ, Wessel K (1997) Neuroprotection by the metabolic antioxidant α-lipoic acid. Free Radic Biol Med 22: 359-378
66. Panigrahi M, Sadguna Y, Shivakumar BR, Kolluri SV, Roy S, Packer L, Ravindranath V (1996) α-Lipoic acid protects against reperfusion injury following cerebral ischemia in rats. Brain Res 717: 184-188
67. Pentikainen MO, Lindstedt KA, Kovanen PT (1995) Inhibition of the oxidative modification of LDL by nitecapone. Arterioscler Thromb Vasc Biol 15: 740-747
68. Riederer P, Sofic E, Rausch WD, Schmidt D, Reynolds GP, Jellinger K, Youdim MBH (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52: 512-520
69. Sam EE, Verbeke N (1995) Free radical scavenging properties of apomorphine enantiomers and dopamine: Possible implication in their mechanism of action in parkinsonism. J Neural Transm PD Sect 10: 115-127
70. Sgaragli GP, Valoti M, Gorelli B, Fusi F, Palmi M, Mantovani P (1993) Calcium antagonist and antiperoxidant properties of some hindered phenols. Br J Pharmacol 110: 369-377
71. Shinobu LA, Beal MF (1997) The role of oxidative processes and metal ions in aging and Alzheimer's disease. In: Connor JR (ed) Metals and oxidative damage in neurological disorders. Plenum Press, New York, pp 237-275
72. Smith CD, Carney JM, Starke-Reed PE, Oliver CN, Stadtman ER, Floyd RA, Markesbery WR (1991) Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc Natl Acad Sci USA 88: 10540-10543
73. Spear N, Aust SD (1995) Effects of glutathione on Fenton reagent-dependent radical production and DNA oxidation. Arch Biochem Biophys 324: 111-116
74. Stadtman ER (1993) Oxidation of free amino acids and amino acid residues in proteins by radiolysis and by metal-catalyzed reactions. Annu Rev Biochem 62: 797-821
75. Terland O, Flatmark T, Tangeras A, Gronberg M (1997) Dopamine oxidation generates an oxidative stress mediated by dopaminc semiquinone and unrelated to reactive oxygen species. J Mol Cell Cardiol 29: 1731-1738
76. Trenam CW, Winyard PG, Morris CJ, Blake DR (1992) Iron promotes oxidative damage in rheumatic diseases. In: Lauffcr RB (ed) Iron and human disease. CRC Press, Boca Raton, pp 395-418
77. Vatessery GT (1997) Vitamin E: Neurochemical aspects and relevance to nervous system disorders. In: Connor JR (ed) Metals and oxidative damage in neurological disorders. Plenum Press, New York, pp 175-188
78. Vimard F, Nouvelot A, Duval D (1996) Cytotoxic effects of an oxidative stress on neuronal-like pheochromocytoma cells (PC12). Biochem Pharmacol 51: 1389-1395
79. Wolz P, Krieglstein J (1996) Neuroprotective effects of α-lipoic acid and its enantiomers demonstrated in rodent models of focal cerebral ischemia. Neuropharmacology 35: 369-375
80. Xiao G, van der Helm D, Hider RC, Rai BL (1996) Molecular modeling studies of a ferric hexadentate 3-hydroxy-2(1H)-pyridone complex and an analog by molecular mechanics, molecular dynamics, and free energy pertubation simulations. J Phys Chem 100: 2345-2352
81. Yamasaki Y, Itoyama Y, Kogure K (1996) Involvement of cytokine production in pathogenesis of transient cerebral ischemic damage. Keio J Med 45: 225-229
82. Youdim MBH, Lavie L, Riederer P (1994) Oxygen free radicals and neurodegeneration in Parkinson's disease: a role for nitric oxide. Ann N Y Acad Sci 738: 64-68
83. Zhao Q, Pahlmark K, Smith ML, Siesjö BK (1994) Delayed treatment with the spin trap α-phenyl-N-tert-butyl nitrone (PBN) reduces infarct size following transient middle cerebral artery occlusion in rats. Acta Physiol Scand 152: 349-350